| Drug name |
Drug type |
Disease/phenotype |
Mechanism of action(MoA) |
Phase |
Status |
Source |
| ULIXERTINIB | Small molecule | none | MAP kinase ERK2 inhibitor | 2 | ['Completed', 'Completed', 'Terminated', 'Active, not recruiting', 'Recruiting', 'Recruiting', 'Completed', 'Recruiting', 'Recruiting'] | ['ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials'] |
| TEMUTERKIB | Small molecule | none | Mitogen-activated protein kinase; ERK1/ERK2 inhibitor | 2 | ['Recruiting', 'Recruiting', 'Recruiting', 'Recruiting', 'Recruiting'] | ['ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials'] |
| MK-8353 | Small molecule | none | MAP kinase ERK2 inhibitor | 1 | ['Terminated', 'Completed', 'Active, not recruiting'] | ['ClinicalTrials', 'ClinicalTrials', 'ClinicalTrials'] |
| KO-947 | Small molecule | none | Mitogen-activated protein kinase; ERK1/ERK2 inhibitor | 1 | ['Terminated'] | ['ClinicalTrials'] |
| RAVOXERTINIB | Small molecule | none | MAP kinase ERK2 inhibitor | 1 | ['Completed'] | ['ClinicalTrials'] |